Drug Profile
PGT 121
Alternative Names: PGT121Latest Information Update: 30 Mar 2022
Price :
$50
*
At a glance
- Originator Theraclone Sciences
- Developer Centre for the AIDS Programme of Research in South Africa; International AIDS Vaccine Initiative; The Ragon Institute of MGH, MIT and Harvard
- Class Antivirals; Cancer vaccines; Monoclonal antibodies
- Mechanism of Action HIV envelope protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported HIV infections
Most Recent Events
- 12 Feb 2022 Pharmacodynamics data from preclinical trials in HIV infection presented at the 29th Conference on Retroviruses and Opportunistic Infections (CROI-2022)
- 28 Nov 2021 No recent reports of development identified for phase-I development in HIV-infections(In adults) in South Africa (SC, Injection)
- 30 Jul 2021 Beth Israel Deaconess Medical Centre plans a phase I/II trial for HIV infection (In adults, In elderly, Combination therapy) in USA (NCT04983030)